Holen Sie sich die Stockscreener-App
263.65
2.23%
-6.4432
Schlusskurs vom Vortag:
$270.09
Offen:
$270.89
24-Stunden-Volumen:
142.69K
Relative Volume:
0.22
Marktkapitalisierung:
$17.29B
Einnahmen:
$1.01B
Nettoeinkommen (Verlust:
$581.90M
KGV:
29.71
EPS:
8.8733
Netto-Cashflow:
$50.57M
1W Leistung:
-1.21%
1M Leistung:
+3.39%
6M Leistung:
+10.07%
1J Leistung:
+30.15%
1-Tages-Spanne:
$262.50
$272.37
1-Wochen-Bereich:
$262.32
$272.47
52-Wochen-Spanne:
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Firmenname
Ascendis Pharma A S
Sektor
Branche
Telefon
-
Adresse
-
Compare ASND vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
263.65 | 17.72B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.05 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.68 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.07 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-17 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Eingeleitet | Stifel | Buy |
| 2023-12-20 | Eingeleitet | Jefferies | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Neutral |
| 2023-04-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-08-30 | Fortgesetzt | Berenberg | Buy |
| 2022-03-28 | Fortgesetzt | Wedbush | Outperform |
| 2022-03-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Market Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-30 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Fortgesetzt | Stifel | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2019-01-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Eingeleitet | Stifel | Buy |
| 2018-04-02 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2017-03-09 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Eingeleitet | Credit Suisse | Outperform |
| 2016-09-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - DirectorsTalk Interviews
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - Yahoo Finance
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Stifel Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - Moomoo
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
Oppenheimer raises Ascendis Pharma stock price target on settlement By Investing.com - Investing.com Australia
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BofA cuts Ascendis Pharma stock price target on settlement impact By Investing.com - Investing.com South Africa
BioMarin announces global settlement with Ascendis - The Pharma Letter
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344 - Moomoo
Ascendis Pharma (ASND) Clears Yuviwel Patent Fight With Global Licensing Deal - simplywall.st
BofA cuts Ascendis Pharma stock price target on settlement impact - Investing.com
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Ascendis Pharma settles patent dispute with US-based Biomarin - medwatch.com
Ascendis Pharma ASND Draws Bullish Targets After Q2 Earnings Surge - timothysykes.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - Stock Titan
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin - Fierce Pharma
Why Ascendis Pharma (ASND) Stock Is Up Today - Quiver Quantitative
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Benzinga
Jefferies lowers Ascendis Pharma stock price target on settlement - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com Australia
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - Yahoo Finance
BioMarin Licenses CNP Program to Ascendis With 20%/18% Royalties, Ends Patent Disputes - TradingView
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - Yahoo Finance
Ascendis Pharma A/S (ASND): Investor Outlook Reveals a Promising 27% Upside Potential in Biotech - DirectorsTalk Interviews
BioMarin and Ascendis settle patent disputes wi... - Pluang
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - PR Newswire
Ascendis Pharma (ASND) Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug - simplywall.st
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating By Investing.com - Investing.com India
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 - Yahoo Finance
Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside - simplywall.st
Finanzdaten der Ascendis Pharma A S-Aktie (ASND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ascendis Pharma A S-Aktie (ASND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HOLTUG LARS | Director |
Sep 02 '26 |
Sale |
264.13 |
236 |
62,335 |
4,000 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):